Suspected Antimonopoly Act Violations and JFTC Inspection Concerning アトル’s Pharmaceutical Tenders for Kyushu Hospitals
First written in FY2022-Q2. 2 of 4 entries say "Restated". Latest entry: FY2023.
0 other companies' latest entry also says "Mitigated".
- FY2023MitigatedAnnual report
「Regarding this matter, 株式会社アトル applied to the Japan Fair Trade Commission for the leniency program, voluntarily reported past violations and fully cooperated with the Commission’s investigation. As a result, among other factors, it has received neither a cease-and-desist order nor a surcharge payment order.」
Regarding the inspection into pharmaceutical bids for hospitals in the Kyushu area involving アトル, the Company disclosed that the Japan Fair Trade Commission had announced a cease-and-desist order and a surcharge payment order, while アトル had received neither order as a result of its leniency application, voluntary reporting and cooperation with the investigation. - FY2023-Q3RestatedAnnual report
「On 9 November 2021, 株式会社アトル, a wholly owned consolidated subsidiary of the Company (Higashi-ku, Fukuoka City), was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals procured by hospitals in the Kyushu area through the National Hospital Organization headquarters.」
The Company continued to disclose the Japan Fair Trade Commission’s on-site inspection of アトル and the suspicion of an Antimonopoly Act violation concerning pharmaceutical bids in the Kyushu area. - FY2022RestatedAnnual report
「On 9 November 2021, 株式会社アトル, a wholly owned consolidated subsidiary of the Company (Higashi-ku, Fukuoka City), was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals procured by hospitals in the Kyushu area through the National Hospital Organization headquarters.」
The Company continued to disclose the Japan Fair Trade Commission’s on-site inspection of アトル and the suspicion of an Antimonopoly Act violation concerning pharmaceutical bids in the Kyushu area. - FY2022-Q2First statedAnnual report
「In November 2021, 株式会社アトル, a wholly owned consolidated subsidiary of the Company (Fukuoka City, Fukuoka), was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals procured by hospitals in the Kyushu area through the National Hospital Organization headquarters.」
The Company newly disclosed that アトル had been subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with pharmaceutical bids for hospitals in the Kyushu area conducted by the National Hospital Organization headquarters. No determination of a violation was disclosed.